Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christin Wilkins

Physician Assistant Fort Worth, TX Physician Assistant

NPI 1831565357 CMS profile 11119725

508 S Adams St, Ste 100, Fort Worth, TX 76104

Open in the dashboard

General payments

$11,491

316 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christin Wilkins of Fort Worth, TX is reported in the CMS Open Payments database as having received $11,491 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,701 35
2024 General $905 50
2023 General $5,281 108
2022 General $2,298 70
2021 General $1,306 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christin Wilkins
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Christin Wilkins were reported at $1,701. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Christin Wilkins Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,306 $132 $37–$438 $132
2022 $2,298 $155 $48–$522 $149
2023 $5,281 $167 $52–$557 $160
2024 $905 $178 $55–$600 $164
2025 $1,701 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $4,390 49 payments
  2. Abbott Laboratories $2,446 30 payments
  3. Novartis Pharmaceuticals Corporation $1,000 60 payments
  4. Pfizer Inc. $792 52 payments
  5. AstraZeneca Pharmaceuticals LP $341 9 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $321 17 payments
  7. Amgen Inc. $239 9 payments
  8. Impulse Dynamics (USA) Inc. $233 6 payments
  9. Janssen Pharmaceuticals, Inc $231 17 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $220 10 payments
  11. Other $1,279 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,292 283 payments
  2. Travel and Lodging $4,170 31 payments
  3. Education $29 2 payments
Products named General payments · program years 2021–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $1,530 19 payments
  2. SYMPLICITY G3 $1,131 14 payments
  3. CARDIOMEMS $572 2 payments
  4. LEQVIO $480 30 payments
  5. VYNDAQEL $425 22 payments
  6. ELIQUIS $382 31 payments
  7. ENTRESTO $367 19 payments
  8. LifeVest $321 17 payments
  9. PAXLOVID $256 21 payments
  10. Repatha $239 9 payments
  11. Other $3,699 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

970

Median for Physician Assistant: 241

Drug cost

$253,859

Median for Physician Assistant: $4,110

Branded share of claims

35.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 160 $133,878
Entresto Sacubitril/Valsartan Brand 43 $41,711
Xarelto Rivaroxaban Brand 33 $35,880
Farxiga Dapagliflozin Propanediol Brand 17 $13,112
Multaq Dronedarone Hcl Brand 12 $9,633
Jardiance Empagliflozin Brand 12 $9,191
Icosapent Ethyl Generic 14 $4,128
Flecainide Acetate Generic 13 $817
Metoprolol Succinate Generic 78 $771
Valsartan Generic 32 $640

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$42,947

Medicare's payments for the services billed

Medicare patients

246

Average age 78

Services billed

717

132 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Ischemic heart disease 61%
Atrial fibrillation 53%
Heart failure 50%
Diabetes 48%
Chronic kidney disease 45%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $174
$174 — —
VYNDAQEL
  • PFIZER INC. $120
$120 — —
ELIQUIS
  • PFIZER INC. $64
$64 160 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $38
$38 — —
Repatha
  • Amgen Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record